Plain-English translation of NCT04512716 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage study testing a new two-part treatment approach for people with aggressive blood cancers (acute lymphoblastic leukemia or diffuse large B-cell lymphoma) that no longer respond to standard chemotherapy. The treatment combines , a radioactive medication that targets cancer cells, followed by therapy, which uses your own immune cells that have been specially engineered in the lab to fight cancer. The study is trying to find the safest and most effective dose of the first medication before giving the immune cells.
People with blood cancers that keep coming back or don't respond to standard chemotherapy have very few treatment options left and a poor outlook. This medication combined with immune cell therapy is designed to offer a new hope for patients in this difficult situation by attacking cancer cells in a completely different way than chemotherapy.
You likely qualify if…
You likely don't qualify if…
You would first undergo a procedure called leukapheresis, in which blood is removed, your immune cells are collected and sent to a lab to be engineered, and your blood is returned to you. Then, you would receive the radioactive medication () as a conditioning treatment, followed by an infusion of your engineered immune cells. You would need to stay in the hospital for close monitoring during the treatment and recovery period, and have follow-up visits to check how well the treatment is working and manage any side effects.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
United States